Cancer
Malignant Cervical Neoplasm
CI-CAN-00007992Explore in graph →
Top-level506 active trials4 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00007992Explore in graph →
Clinical trials
1,994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06353061 | Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer | unknown | Phase 2 | 51 | Peking Union Medical College HospitalOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06237257 | A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer | unknown | Phase 2 | 56 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT05554276 | Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer(PD-1) | unknown | Phase 2 | 36 | Shanghai Jiao Tong University Affiliated Sixth People's HospitalOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT03340376 | Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer | unknown | Phase 2 | 48 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06455072 | Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer | unknown | Phase 2 | 37 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 12, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT06241235 | Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | unknown | Phase 1 / Phase 2 | 48 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05910177 | Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin | unknown | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06223308 | A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 54 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT05084677 | Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer | unknown | Phase 2 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT00997009 | Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer(MITO CERV 2) | unknown | Phase 2 | 108 | National Cancer Institute, NaplesOTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT05805358 | Hyperpolarized 13C MRI for Cancer Immunotherapy(DNPSPIO) | unknown | Phase 2 | 90 | Chang Gung Memorial HospitalOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05606263 | Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer(GCR-05) | unknown | Phase 2 | 55 | Xi'an Jiaotong UniversityOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT05824494 | Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors | unknown | Phase 2 | 58 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT00492778 | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer | unknown | Phase 2 | 165 | GOG FoundationNETWORK | 2 | Mar 29, 2023 | clinicaltrials |
| NCT05437692 | Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer | unknown | Phase 2 | 19 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05557565 | A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer | unknown | Phase 2 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT04641728 | Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer | unknown | Phase 2 | 28 | Saitama Medical University International Medical CenterOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05179317 | Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05247619 | A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 49 | Zhejiang Cancer HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05444374 | A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer | unknown | Phase 2 | 48 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03827837 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | unknown | Phase 2 | 265 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05342506 | Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Apr 22, 2022 | clinicaltrials |
| NCT05311566 | PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer | unknown | Phase 2 | 92 | Lei LiOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05310383 | Tislelizumab and Radiotherapy for Recurrent Cervical Cancer | unknown | Phase 2 | 58 | Lei LiOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05321329 | Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients(ACAPP) | unknown | Phase 2 | 28 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05310331 | Donafenib for Recurrent Cervical Cancer | unknown | Phase 2 | 20 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05259540 | Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma | unknown | Phase 2 | 42 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT05290935 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial | unknown | Phase 2 | 122 | Lei LiOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT03976973 | BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei | unknown | Phase 2 | 62 | Mucpharm Pty LtdINDUSTRY | 0 | Mar 15, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03668639 | Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin | unknown | Phase 2 / Phase 3 | 80 | Christina RuhlmannOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT05151549 | A Study of Carilizumab Combined With Concurrent Chemoradiotherapy | unknown | Phase 2 | 46 | Hunan Cancer HospitalOTHER | 0 | Dec 9, 2021 | clinicaltrials |
| NCT05137171 | AK105 Combined With Anlotinib in Patients With Cervical Cancer | unknown | Phase 2 | 36 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Nov 30, 2021 | clinicaltrials |
| NCT04238988 | Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer(MITO CERV 3) | unknown | Phase 2 | 45 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT04974827 | A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer | unknown | Phase 2 | 46 | Hunan Cancer HospitalOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04973904 | Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer | unknown | Phase 2 | 35 | Peking Union Medical College HospitalOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04918628 | Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer(CRTCP) | unknown | Phase 2 | 50 | Taizhou HospitalOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04395612 | Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer(CQGOG0101) | unknown | Phase 2 | 38 | Chongqing University Cancer HospitalOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT04884906 | Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04800978 | Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy | unknown | Phase 2 | 37 | Samsung Medical CenterOTHER | 0 | Mar 16, 2021 | clinicaltrials |
| NCT04789941 | How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix | unknown | Phase 2 | 50 | Assiut UniversityOTHER | 0 | Mar 10, 2021 | clinicaltrials |
| NCT03808857 | A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive | unknown | Phase 2 | 80 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04664244 | Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma | unknown | Phase 2 | 43 | Lei LiOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT04635956 | Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas | unknown | Phase 2 | 20 | Lei LiOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT03295526 | Selective Pelvic Lymphadenectomy for IB-IIA Cervical Cancer | unknown | Phase 2 | 200 | Fudan UniversityOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT04368273 | Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.(CCRT+PD-1) | unknown | Phase 1 / Phase 2 | 30 | Peking University Third HospitalOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT04310774 | CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer | unknown | Phase 1 / Phase 2 | 200 | Peking Union Medical College HospitalOTHER | 0 | Mar 19, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jan 14, 2025source: clinicaltrials